4
Changes in Ownership
Kalaris Therapeutics, Inc. Filed Acc 0001209191-23-043121
Chief Executive Officer sold 8,342 shares at $3.56 ($29,710)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Brainard Diana Chief Executive Officer | 2023-07-19 | Sale 10b5-1 | −8,342 | $3.56 | $29,710 | 907,299 | D: show line 1 in the form |
| Open-market sales · 8,342 sh · avg $3.56 · $29,710 | |||||||
Loading xslF345X05/doc4.xml…